Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOURLIGHT-1: PF-07220060 + Fulvestrant in Advanced Breast Cancer
NCT06105632Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of atirmociclib in breast cancer, sponsored by Pfizer. Started Jan 2024; status: active, not recruiting.
02
Drugs
atirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06105632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06105632.